Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Obesity drug enthusiasm can continue in 2024: Mizuho's Jared Holz
06:40pm, Wednesday, 27'th Dec 2023
Mizuho's Jared Holz joins 'Fast Money' to talk enthusiasm surrounding obesity drugs and if that can endure into 2024.
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
07:50am, Wednesday, 27'th Dec 2023
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceutic
Can This Red-Hot Stock Beat the Market Again in 2024?
04:00pm, Friday, 22'nd Dec 2023
Eli Lilly could earn an important approval in 2024. The company's financial results could improve, too.
Looking Beyond Tech: 7 High-Growth Stocks for Substantial Returns
07:51am, Friday, 22'nd Dec 2023
The tech market is surging, with a remarkable 40% year-to-date increase in the Nasdaq-100 Technology Sector. The buzz around high-growth stocks in fields including AI and cloud computing is palpable
These 3 Big Pharma Stocks Are Making Big Plays With AI
07:15am, Friday, 22'nd Dec 2023
Big drug companies want to use artificial intelligence for a handful of purposes. Finding leads to make medicines more efficiently is one in-demand application.
Eli Lilly (LLY) Rises Yet Lags Behind Market: Some Facts Worth Knowing
06:47pm, Thursday, 21'st Dec 2023
The latest trading day saw Eli Lilly (LLY) settling at $572, representing a +0.31% change from its previous close.
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
10:32am, Thursday, 21'st Dec 2023
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
09:45am, Thursday, 21'st Dec 2023
The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
11:17am, Wednesday, 20'th Dec 2023
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
2 Unstoppable Growth Stocks to Buy in 2024
09:30am, Wednesday, 20'th Dec 2023
Eli Lilly's sales growth should accelerate next year now that Zepbound has obtained approval. PDD Holdings owns Temu, which is one of the most popular e-commerce sites in the world today.
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
07:00am, Wednesday, 20'th Dec 2023
Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.
5 Big Drug Stocks That May Continue to Outperform in 2024
10:31am, Monday, 18'th Dec 2023
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
09:15am, Monday, 18'th Dec 2023
Understanding what's hot and what's not is key to investing in biopharma. Drugs like Ozempic are going to continue being very popular next year.
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
08:00am, Sunday, 17'th Dec 2023
2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance coverage and unpleasant side effects.
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.
05:55am, Saturday, 16'th Dec 2023
A recent study found that patients who quit taking Lilly's Zepbound regain much of their weight. Investors viewed this as bad news for Lilly, but it's actually good news.
